 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Survival of Elderly Patients with Colon Cancer Treated with Chemotherapy
5 March 2002 | Volume 136 Issue 5 | Page I19
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians–American Society of Internal Medicine.
The summary below is from the full report titled "Survival Associated with 5-Fluorouracil-Based Adjuvant Chemotherapy among Elderly Patients with Node-Positive Colon Cancer." It is in the 5 March 2002 issue of Annals of Internal Medicine (volume 136, pages 349-357). The authors are V Sundararajan, N Mitra, JS Jacobson, VR Grann, DF Heitjan, and AI Neugut.
What is the problem and what is known about it so far?
Colon cancer is cancer of the large intestine. If colon cancer is found in its early stages, it can often be successfully treated with surgery. If colon cancer has spread outside of the colon to the lymph nodes (node-positive colon cancer), the addition of chemotherapy that includes the drug 5-fluorouracil (5-FU) helps patients survive longer. However, such treatment is less common in patients 65 years of age and older than it is among younger patients. Some think that doctors are reluctant to advise older patients to have chemotherapy because studies of 5-FU therapy have included few older patients. It is not known whether older patients do as well after 5-FU therapy as younger patients.
Why did the researchers do this particular study?
To see whether patients with colon cancer who were at least 65 years of age and received 5-FU therapy in addition to surgery lived longer than those who were treated with surgery alone.
Who was studied?
The study included 4768 patients at least 65 years of age who received a diagnosis of node-positive colon cancer from 1992 to 1996, were covered by Medicare, and were included in a large, U.S. government-sponsored database of cancer care.
How was the study done?
The researchers determined how long patients survived and whether they received 5-FU therapy in addition to surgery. While accounting for other factors, such as noncancer illnesses, that might influence survival, the researchers then used statistical methods to see whether any survival benefit was associated with chemotherapy.
What did the researchers find?
About half of the study patients received 5-FU therapy. Patients treated with 5-FU therapy were less likely to die during the study than patients who did not get this treatment.
What were the limitations of the study?
Patients who received 5-FU may have been generally healthier, in ways that the researchers were unable to account for, than patients who did not.
What are the implications of the study?
Among patients 65 years of age and older, those who receive 5-FU therapy for node-positive colon cancer do better than those who receive surgery alone. The benefits observed in this study were similar to those reported for younger patients. Older age alone should not be a barrier to receiving 5-FU therapy for node-positive colon cancer.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  D. Papamichael, R. Audisio, J.-C. Horiot, B. Glimelius, J. Sastre, E. Mitry, E. Van Cutsem, M. Gosney, C.-H. Kohne, and M. Aapro Treatment of the elderly colorectal cancer patient: SIOG expert recommendations Ann. Onc., October 15, 2008; (2008) mdn532v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Keating, M. B. Landrum, C. N. Klabunde, R. H. Fletcher, S. O. Rogers, W. R. Doucette, D. Tisnado, S. Clauser, and K. L. Kahn Adjuvant Chemotherapy for Stage III Colon Cancer: Do Physicians Agree About the Importance of Patient Age and Comorbidity? J. Clin. Oncol., May 20, 2008; 26(15): 2532 - 2537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Kohne, G. Folprecht, R. M. Goldberg, E. Mitry, and P. Rougier Chemotherapy in Elderly Patients with Colorectal Cancer Oncologist, April 1, 2008; 13(4): 390 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Folprecht, M. T. Seymour, L. Saltz, J.-Y. Douillard, H. Hecker, R. J. Stephens, T. S. Maughan, E. Van Cutsem, P. Rougier, E. Mitry, et al. Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials J. Clin. Oncol., March 20, 2008; 26(9): 1443 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Morris, C. Platell, and B. Iacopetta Tumor-Infiltrating Lymphocytes and Perforation in Colon Cancer Predict Positive Response to 5-Fluorouracil Chemotherapy Clin. Cancer Res., March 1, 2008; 14(5): 1413 - 1417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Muss, L. Biganzoli, D. J. Sargent, and M. Aapro Adjuvant Therapy in the Elderly: Making the Right Decision J. Clin. Oncol., May 10, 2007; 25(14): 1870 - 1875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Sanoff, H. Bleiberg, and R. M. Goldberg Managing Older Patients With Colorectal Cancer J. Clin. Oncol., May 10, 2007; 25(14): 1891 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer Adjuvant Treatment of Colorectal Cancer CA Cancer J Clin, May 1, 2007; 57(3): 168 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Luo, S. H. Giordano, J. L. Freeman, D. Zhang, and J. S. Goodwin Referral to Medical Oncology: A Crucial Step in the Treatment of Older Patients with Stage III Colon Cancer Oncologist, October 1, 2006; 11(9): 1025 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Elkin, A. Hurria, N. Mitra, D. Schrag, and K. S. Panageas Adjuvant Chemotherapy and Survival in Older Women With Hormone Receptor-Negative Breast Cancer: Assessing Outcome in a Population-Based, Observational Cohort J. Clin. Oncol., June 20, 2006; 24(18): 2757 - 2764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Neugut, M. Matasar, X. Wang, R. McBride, J. S. Jacobson, W.-Y. Tsai, V. R. Grann, and D. L. Hershman Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the Elderly J. Clin. Oncol., May 20, 2006; 24(15): 2368 - 2375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Viotti, C. Vigliano, B. Lococo, G. Bertocchi, M. Petti, M. G. Alvarez, M. Postan, and A. Armenti Long-Term Cardiac Outcomes of Treating Chronic Chagas Disease with Benznidazole versus No Treatment: A Nonrandomized Trial Ann Intern Med, May 16, 2006; 144(10): 724 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Dobie, L.-M. Baldwin, J. A. Dominitz, B. Matthews, K. Billingsley, and W. Barlow Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst, May 3, 2006; 98(9): 610 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Unger, C. A. Coltman Jr, J. J. Crowley, L. F. Hutchins, S. Martino, R. B. Livingston, J. S. Macdonald, C. D. Blanke, D. R. Gandara, E. D. Crawford, et al. Impact of the Year 2000 Medicare Policy Change on Older Patient Enrollment to Cancer Clinical Trials J. Clin. Oncol., January 1, 2006; 24(1): 141 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Jessup, A. Stewart, F. L. Greene, and B. D. Minsky Adjuvant Chemotherapy for Stage III Colon Cancer: Implications of Race/Ethnicity, Age, and Differentiation JAMA, December 7, 2005; 294(21): 2703 - 2711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Edwards, M. L. Brown, P. A. Wingo, H. L. Howe, E. Ward, L. A. G. Ries, D. Schrag, P. M. Jamison, A. Jemal, X. C. Wu, et al. Annual Report to the Nation on the Status of Cancer, 1975-2002, Featuring Population-Based Trends in Cancer Treatment J Natl Cancer Inst, October 5, 2005; 97(19): 1407 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wasil and S. M. Lichtman Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly Oncologist, September 1, 2005; 10(8): 602 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Lamont, J. E. Herndon II, J. C. Weeks, I. C. Henderson, R. Lilenbaum, R. L. Schilsky, N. A. Christakis, and for the Cancer and Leukemia Group B Criterion Validity of Medicare Chemotherapy Claims in Cancer and Leukemia Group B Breast and Lung Cancer Trial Participants J Natl Cancer Inst, July 20, 2005; 97(14): 1080 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. E. P. P. Lemmens, A. H. van Halteren, M. L. G. Janssen-Heijnen, G. Vreugdenhil, O. J. Repelaer van Driel, and J. W. W. Coebergh Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity Ann. Onc., May 1, 2005; 16(5): 767 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Alberts, D. J. Sargent, S. Gill, and C. L. Loprinzi In Reply J. Clin. Oncol., January 20, 2005; 23(3): 654 - 655. [Full Text] [PDF]
|
|
|
|
|
|
G. Folprecht, D. Cunningham, P. Ross, B. Glimelius, F. Di Costanzo, J. Wils, W. Scheithauer, P. Rougier, E. Aranda, H. Hecker, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials Ann. Onc., September 1, 2004; 15(9): 1330 - 1338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Labianca, R. Fossati, A. Zaniboni, V. Torri, S. Marsoni, D. Nitti, L. Boffi, M. Scatizzi, B. Tardio, N. Mastrodonato, et al. Randomized Trial of Intraportal and/or Systemic Adjuvant Chemotherapy in Patients With Colon Carcinoma J Natl Cancer Inst, May 19, 2004; 96(10): 750 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. McWilliams, A. M. Zaslavsky, E. Meara, and J. Z. Ayanian Impact of Medicare Coverage on Basic Clinical Services for Previously Uninsured Adults JAMA, August 13, 2003; 290(6): 757 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van Rijnsoever, H. Elsaleh, D. Joseph, K. McCaul, and B. Iacopetta CpG Island Methylator Phenotype Is an Independent Predictor of Survival Benefit from 5-Fluorouracil in Stage III Colorectal Cancer Clin. Cancer Res., August 1, 2003; 9(8): 2898 - 2903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Z. Ayanian, M. B. Landrum, E. Guadagnoli, and P. Gaccione Specialty of Ambulatory Care Physicians and Mortality among Elderly Patients after Myocardial Infarction N. Engl. J. Med., November 21, 2002; 347(21): 1678 - 1686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Iwashyna and E. B. Lamont Effectiveness of Adjuvant Fluorouracil in Clinical Practice: A Population-Based Cohort Study of Elderly Patients With Stage III Colon Cancer J. Clin. Oncol., October 1, 2002; 20(19): 3992 - 3998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Neugut, A. T. Fleischauer, V. Sundararajan, N. Mitra, D. F. Heitjan, J. S. Jacobson, and V. R. Grann Use of Adjuvant Chemotherapy and Radiation Therapy for Rectal Cancer Among the Elderly: A Population-Based Study J. Clin. Oncol., June 1, 2002; 20(11): 2643 - 2650. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
